Please ensure Javascript is enabled for purposes of website accessibility

Why Sarepta Therapeutics Inc. Soared 44% Higher in March

By Brian Feroldi - Apr 9, 2016 at 9:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News of a new date for an advisory committee meeting has put traders in a good mood.

Image by Unsplash via pixabay

What: Shares of Sarepta Therapeutics (SRPT 3.64%), a clinical-stage biopharmaceutical company primarily focused on treating Duchenne muscular dystrophy, rose 44% during March, according to data from S&P Global Market Intelligence.

SRPT Chart

So what: A handful of news announcements look responsible for last month's gains:

  • First, the FDA has rescheduled its advisory committee meeting to review Sarepta's NDA for its DMD drug, eteplirsen. The meeting was previously scheduled for Jan. 20, but that was cancelled due to a storm in the Washington, D.C., area. The new date for the meeting is April 25, and the agency is still set to make a decision on the drug by May 26. 
  • Next, a letter was posted to the UCLA website that urged the FDA to approve eteplirsen. The letter was written by two directors of the Center for Duchenne Muscular Dystrophy at UCLA and it was signed by 34 healthcare providers that specialize in DMD research.
  • Finally, the company announced plans to consolidate its operations, closing its Oregon facility and moving some of its employees to its sites in Massachusetts. 

Now what: It's tough to predict what kind of response the committee will have for eteplirsen. On the one hand, documents released by the FDA ahead of the drug's prior advisory committee meeting were quite harsh. On the other hand, eteplirsen has been granted Priority Review status, there are no adequate therapy options for DMD, and patient and provider support is huge -- meaning the committee might be willing to be more flexible.

Companies that make drugs aimed at treating DMD haven't had any luck the with FDA at all. Case in point: BioMarin's (BMRN 0.31%)  Kyndrisa was outright rejected by the FDA a few months back. BioMarin has since turned its efforts toward getting Kyndrisa approval in Europe, but given the FDA's rebuke, the approval seems unlikely.

In addition, PTC Therapeutics (PTCT 3.85%) received a "refuse-to-file" letter from the FDA for its DMD treatment Translarna. The agency stated that the application wasn't complete enough for the FDA to conduct a full review. That came as a bit of a shock to PTC Therapeutics, as Translarna had already sailed through the regulatory approval process in Europe.  

Given the extreme uncertainty surrounding Sarepta's near-term future, I have a hard time being even remotely interested in purchasing shares. For those who are interested, it probably makes sense to watch how the advisory committee meeting plays out before you consider investing.

Brian Feroldi has no position in any stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
BMRN
$96.00 (0.31%) $0.30
Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$113.07 (3.64%) $3.97
PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
PTCT
$53.71 (3.85%) $1.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.